Design potential selective inhibitors for human leukocyte common antigen-related (PTP-LAR) with fragment replace approach.

Wu, Jing-Wei; Zhang, Huan; Li, Wei-Ya; Tang, Xue; Li, Hong-Lian; Lu, Xin-Hua; Zheng, Zhi-Hui; Ma, Ying; Wang, Run-Ling

Wu, Jing-Wei; Zhang, Huan; Li, Wei-Ya; Tang, Xue; Li, Hong-Lian; Lu, Xin-Hua; Zheng, Zhi-Hui; Ma, Ying; Wang, Run-Ling.

Afiliación

Wu JW; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, China.
Zhang H; Department of Pharmacy, Tianjin Medical University General Hospital, Tianjin, China.
Li WY; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, China.
Tang X; Tasly Research Institute, Tasly Holding Group Co., Ltd, Tianjin, China.
Li HL; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, China.
Lu XH; New Drug Research and Development Center of North China Pharmaceutical Group Corporation, National Microbial Medicine Engineering and Research Center, Hebei Industry Microbial Metabolic Engineering &Technology Research Center, Key Laboratory for New Drug Screening Technology of Shijiazhuang City
Zheng ZH; New Drug Research and Development Center of North China Pharmaceutical Group Corporation, National Microbial Medicine Engineering and Research Center, Hebei Industry Microbial Metabolic Engineering &Technology Research Center, Key Laboratory for New Drug Screening Technology of Shijiazhuang City
Ma Y; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, China.
Wang RL; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, China.

J Biomol Struct Dyn ; 38(18): 5338-5348, 2020 Nov.

Article en En | MEDLINE | ID: mdl-31787068

Asunto(s)

Diabetes Mellitus; Inhibidores Enzimáticos; Antígenos Comunes de Leucocito; Simulación por Computador; Diabetes Mellitus/tratamiento farmacológico; Antígenos HLA; Humanos

Palabras clave

PTP-LAR; docking; fragment replace; molecular dynamics; synthesis

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antígenos Comunes de Leucocito / Diabetes Mellitus / Inhibidores Enzimáticos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Biomol Struct Dyn Año: 2020 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google